The Role of Genetic Factors in the Development of Atopic Dermatitis in the Kazakh Population

Preventive and Personalized Medicine (2021-2023)

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05090631

Enrollment

600

Registered

2021-10-25

Start date

2021-10-23

Completion date

2023-01-20

Last updated

2023-03-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atopic Dermatitis

Keywords

GWAS

Brief summary

This is a GWAS study that aims to identify possible candidate genes associate to atopic dermatitisby exploring single nucleotide polymorphism (SNP) in a group of atopic dermatitis, in the Kazakh population. The investigators hypothesize that the careful phenotyping of the subject sand matching with increase the power to find SNP significantly associate with atopic dermatitis

Detailed description

A genome-wide association study (GWAS) is an approach used in genetics research to associate specific genetic variations with particular diseases. The method involves scanning the genomes from many different people and looking for genetic markers that can be used to predict the presence of a disease. Once such genetic markers are identified, they can be used to understand how genes contribute to the disease and develop better prevention and treatment strategies.

Interventions

GENETICDNA analysis

GWAS

Study design

Observational model

OTHER

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 45 Years

Healthy volunteers

Inclusion criteria

* Persons with various forms of a confirmed diagnosis of atopic dermatitis; * The age of the patients is from 18 to 45+ years; * Persons of Kazakh nationality, whose paternal and maternal grandparents are Kazakhs. * Persons who are able and willing to provide written informed consent; * Persons capable and willing to comply with the research protocol;

Exclusion criteria

* Persons under the age of 18; * Patients with severe concomitant systemic diseases, including cardiovascular, respiratory, hepatic and renal failure * Patients with severe infectious processes (sepsis, abscess, hepatitis B and C, HIV) * Persons with mental illness. * Persons taking corticosteroid drugs, immunosuppressants within the last month; * Persons who, in the opinion of the researcher, are mentally or legally incapacitated, which prevents obtaining informed consent; * Pregnant or lactating women; * Tuberculosis of any localization in the active phase and in history; * Severe and decompensated diseases of the liver and kidneys, cardiovascular system; * Severe and decompensated course of endocrine diseases; * Autoimmune diseases; * Systemic diseases; * Oncological diseases;

Design outcomes

Primary

Measure	Time frame	Description
number of SNPs associated with atopic dermatitis	1 year	Using GWAS to identify candidate genes associate with atopic dermatitis

Countries

Kazakhstan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026